meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
4
mHNSCC - L2 - PDL1 negative
2
mHNSCC - L2 - PDL1 positive
1
hepatocell cancer (HCC)
1
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
All patients
Age < 65y (younger)
ECOG 0
ECOG 1
Gender, male
P16 negative (HPV)
P16 positive (HPV)
PD-L1 < 1%
PD-L1 < 10%
PD-L1 < 5%
PD-L1 > 1%
PD-L1 > 10%
PD-L1 > 5%
smoker (current or former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
objective responses (ORR)
objective responses (ORR) (extension)
PFS (extension)
progression or deaths (PFS)
TRAE (any grade)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
Acute kidney injury TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Eczema TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Erythema TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
Hepatobiliary disorders TRAE (grade 3-4)
Hypersensitivity TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Mucosal inflammation TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)
Peripheral neuropathy TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Renal and urinary disorders TRAE (grade 3-4)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Skin exfoliation TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Urticaria TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Weight decreased TRAE (grade 3-4)
Rash AE (grade 3-4)
deaths (OS)
mHNSCC - L2 - all population
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC)
1
certainty unassessable
statistically conclusive
-28%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open